文献速递消化道肿瘤放疗姑息放疗与转移瘤

S-1联合奥沙利铂术前放化疗治疗局部晚期直肠癌的多中心II期研究长期结果(JACCRO CC-04:SHOGUN试验)

Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
PubMed 文献 · Radiother Oncol · 2019-02-26

该多中心II期研究纳入45例病理确诊的局部晚期直肠癌(cT3-T4,任何N)患者,接受口服S-1联合奥沙利铂及放疗(总剂量50.4 Gy/28次),主要终点pCR率为27.3%(12/44),R0切除率95.5%,3年局部复发率0%,3年DFS率67.5%,3年OS率93.0%,无4级不良事件,3级不良事件发生率11.1%。作者认为在S-1术前放化疗基础上加用奥沙利铂可能可行,并较标准治疗带来更好的局部控制。

要点

  • 44例手术患者中pCR率27.3%(12/44),R0切除率95.5%(42/44)。
  • 3年局部复发率0%,但13例(30.0%)出现远处转移,8例肺转移、4例肝转移,3例死于转移性疾病。
  • 无4级不良事件,3级不良事件发生率11.1%。

核心结论

  • 作者认为在S-1术前放化疗基础上加用奥沙利铂可能可行,并较标准治疗带来更好的局部控制。
  • 研究显示高pCR率、无严重毒性、随访结果良好且局部区域控制良好。

研究设计与样本

  • 多中心II期研究,在日本6个中心纳入45例病理组织学确诊的局部晚期直肠癌(cT3-T4,任何N)患者。

主要发现

  • pCR率为27.3%(12/44),R0切除率为95.5%(42/44)。
  • T降期率59.1%(26/44),N降期率65.9%(29/44),合并病理降期率79.5%(35/44)。
  • 无4级不良事件,11.1%的患者发生3级不良事件。
  • 累积3年局部复发率0%,但13例(30.0%)发生远处转移,其中肺转移8例、肝转移4例,3例死于转移性疾病。
  • 44例患者3年DFS率67.5%(中位随访36.3个月),3年OS率93.0%(中位随访39.6个月)。

关键数值与推荐

  • pCR组(12例)与非pCR组(32例)的3年DFS率分别为91.7%和58.1%,3年OS率分别为100%和90.3%。
  • 放疗方案为1.8 Gy/天,总剂量50.4 Gy/28次,放疗第3周设化疗间歇。
  • 化疗方案为口服S-1 80 mg/m2/天(第1-5、8-12、22-26、29-33天)联合输注奥沙利铂60 mg/m2/天(第1、8、22、29天)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The study was designed to evaluate the safety and efficacy of adding oxaliplatin to py (CRT) with S-1 in patients with locally advanced rectal carcinoma (LARC). We report here the final results of the study. PATIENTS AND METHODS: Patients with histopathologically confirmed LARC (cT3-T4, any N) were eligible. They received oral S-1 (80 mg/m2/day on days 1-5, 8-12, 22-26, and 29-33) and infusional oxaliplatin (60 mg/m2/day on days 1, 8, 22, 29) plus radiotherapy (1.8 Gy/day, total dose of 50.4 Gy in 28 fractions), with a chemotherapy gap in the third week of radiotherapy. Primary endpoint of the study was pathological complete response (pCR) rate. Secondary endpoints were rates of R0 resection, down-staging, cumulative 3-year local recurrence, 3-year disease-free survival (DFS), and toxicity. RESULTS: Forty-five patients were enrolled at six centers in Japan. All patients received CRT, and 44 underwent operation. The pCR rate was 27.3% (12/44). The R0 resection rate was 95.5% (42/44). T-down-staging rate was 59.1% (26/44), and N-down staging rate was 65.9% (29/44); the combined pathological down-staging rate was 79.5% (35/44). There were no grade 4 adverse events, but 11.1% of the patients had grade 3 adverse events. Cumulative 3-year local recurrence rate was 0%. However, 13 (30.0%) patients suffered from distant metastasis, and one patient suffered from secondary esophageal cancer that was unrelated to rectal cancer. Eight patients had lung metastasis, 4 had liver metastasis, and 3 patients died of the metastatic disease. The 3-year DFS rate of the 44 patients was 67.5% (median follow-up 36.3 months), and the 3-year overall survival (OS) rate was 93.0% (median follow-up 39.6 months). The patients were then divided into the pCR (12 patients) group and non pCR (32 patients) group. The 3-year rate of DFS for each group was 91.7% and 58.1% and that of OS was 100% and 90.3%, respectively. CONCLUSIONS: The study showed a high pCR rate with no severe toxicity, good follow-up results, and good loco-regional control. Therefore, addition of oxaliplatin to preoperative CRT with S-1 in patients with LARC might be feasible and lead to better local control than standard treatment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kondo K, Matsusaka S, Ishihara S, et al. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial). Radiother Oncol. 2019. PMID: 31005216. doi:10.1016/j.radonc.2019.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。